FDA approves long-acting formulation of J&J schizophrenia med

The FDA gave the green light to Johnson & Johnson's ($JNJ) Invega Trinza, which is injected four times a year, making it the longest-acting schizophrenia drug on the market. Previous formulation Invega Sustenna earned $1.5 billion in 2014, so Invega Trinza is likely to become a blockbuster. More

Suggested Articles

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

It’s not exactly going to be smooth sailing for Allergan’s multidose bottle version of dry-eye med Restasis. As it finally gets the green light from the FDA, a…

Counting on a novel nasal-spray device to set it apart from its rivals, drug delivery specialist OptiNose is preparing to file its new chronic rhinosinusitis…